Sun Pharmaceuticals advanced 2.31% to Rs 1,568 after the European Medicines Agency (EMA) validated the submission of the marketing authorization application (MAA) for Nidlegy, which was finalized on 3 June 2024.
| Subscribe To Our Free Newsletter |
The Most Valuable Commodity Is Information!
